Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFLOAT
2024-513324-42-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atrial arrhythmia, Atrial fibrillation (AFib), atrial flutter (AFL) and 1 more comparing flecainide with placebo (2 arms). Planned start May 2024; status: authorised.
02
Drugs
flecainide
03
Conditions
atrial arrhythmiaAtrial fibrillation (AFib)atrial flutter (AFL)atrial tachycardia (AT)
Beyond the preview
Go deeper on 2024-513324-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513324-42-00.